New York, New York--(Newsfile Corp. - February 20, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Inovio Pharmaceuticals, Inc. (NASDAQ: INO) between October 10, 2023 and December 26, 2025, inclusive (the "Class Period"), of the important April 7, 2026 lead plaintiff deadline.SO WHAT: If you purchased Inovio securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee a ...

Core Viewpoint - Rosen Law Firm is reminding investors who purchased PomDoctor Ltd. securities during the specified Class Period of the upcoming lead plaintiff deadline for a class action lawsuit [1] Group 1: Class Action Details - The class action lawsuit has been filed against PomDoctor Ltd. for misleading statements and fraudulent activities during the Class Period from October 9, 2025, to December 11, 2025 [4] - Investors who purchased PomDoctor securities during this period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1][4] - The deadline to move the Court to serve as lead plaintiff is April 7, 2026, and a lead plaintiff acts on behalf of other class members [2] Group 2: Allegations Against PomDoctor - The lawsuit alleges that PomDoctor was involved in a fraudulent stock promotion scheme that included misinformation on social media and impersonation of financial professionals [4] - It is claimed that insiders used offshore accounts to facilitate the coordinated dumping of shares during a price inflation campaign [4] - The public statements made by PomDoctor omitted critical information regarding false rumors and artificial trading activity that influenced the stock price [4] Group 3: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest securities class action settlement against a Chinese company [3] - The firm was ranked No. 1 by ISS Securities Class Action Services for the number of settlements in 2017 and has consistently ranked in the top 4 since 2013 [3] - In 2019, the firm secured over $438 million for investors, showcasing its capability in recovering significant amounts for clients [3]

Core Viewpoint - A class action lawsuit has been filed against PayPal Holdings, Inc. for allegedly providing misleading information regarding its financial targets and growth potential during the specified Class Period from February 25, 2025, to February 2, 2026 [1][5]. Group 1: Lawsuit Details - The lawsuit claims that PayPal's management provided overly optimistic statements about the company's growth potential and its ability to execute on new initiatives, while concealing material adverse facts about the salesforce's readiness [5]. - Investors who purchased PayPal common stock during the Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. Group 2: Legal Representation - The Rosen Law Firm, which is leading the class action, has a strong track record in securities class actions, having achieved significant settlements for investors, including over $438 million in 2019 [4]. - Investors interested in joining the class action can do so by submitting a form or contacting the firm directly [3][6].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased PomDoctor Ltd. securities between October 9, 2025, and December 11, 2025, of the April 7, 2026, deadline to become a lead plaintiff in a class action lawsuit [1]. Group 1: Class Action Details - Investors who bought PomDoctor securities during the specified period may be eligible for compensation without any out-of-pocket costs through a contingency fee arrangement [1]. - A class action lawsuit has already been filed, and interested parties can join by contacting Rosen Law Firm [2][5]. - The deadline to move the Court to serve as lead plaintiff is April 7, 2026, with the lead plaintiff representing other class members in the litigation [2]. Group 2: Law Firm Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest securities class action settlement against a Chinese company and being ranked No. 1 for the number of settlements in 2017 [3]. - The firm has recovered hundreds of millions of dollars for investors, including over $438 million in 2019 alone [3]. - Founding partner Laurence Rosen was recognized as a Titan of Plaintiffs' Bar by Law360 in 2020, and many attorneys at the firm have received accolades from Lawdragon and Super Lawyers [3]. Group 3: Case Allegations - The lawsuit alleges that PomDoctor made false or misleading statements and failed to disclose critical information, including involvement in a fraudulent stock promotion scheme and insider trading activities [4]. - It is claimed that insiders used offshore accounts to facilitate the dumping of shares during a price inflation campaign, and that PomDoctor's public statements omitted mention of false rumors and artificial trading activity [4]. - As a result of these actions, the positive statements made by PomDoctor regarding its business and prospects were materially misleading [4].

New York, New York--(Newsfile Corp. - February 18, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of BellRing Brands, Inc. (NYSE: BRBR) between November 19, 2024 and August 4, 2025, both dates inclusive (the "Class Period"), of the important March 23, 2026 lead plaintiff deadline.SO WHAT: If you purchased BellRing securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency f ...

NEW YORK, Feb. 18, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Bath & Body Works, Inc. (NYSE: BBWI) between June 4, 2024 and November 19, 2025, both dates inclusive (the “Class Period”), of the important March 16, 2026 lead plaintiff deadline. SO WHAT: If you purchased Bath & Body Works securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee ar ...

Core Viewpoint - Rosen Law Firm is reminding investors who purchased common stock of Ultragenyx Pharmaceutical Inc. during the specified class period of the upcoming lead plaintiff deadline for a class action lawsuit [1]. Group 1: Class Action Details - Investors who bought Ultragenyx common stock between August 3, 2023, and December 26, 2025, may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by April 6, 2026 [3]. Group 2: Law Firm Credentials - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions, highlighting its own achievements, including the largest securities class action settlement against a Chinese company [4]. - The firm has consistently ranked among the top firms for securities class action settlements, recovering hundreds of millions of dollars for investors, including over $438 million in 2019 alone [4]. Group 3: Case Background - The lawsuit alleges that Ultragenyx's defendants provided misleading information regarding the expected results of its Phase III studies for setrusumab (UX 143) in treating Osteogenesis Imperfecta [5]. - It is claimed that while setrusumab increased bone density, it did not correlate with a decrease in annualized fracture rates, contrary to the positive statements made by the defendants [6].

New York, New York--(Newsfile Corp. - February 18, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of BlackRock TCP Capital Corp. (NASDAQ: TCPC) between November 6, 2024, and January 23, 2026, inclusive (the "Class Period"), of the important April 6, 2026 lead plaintiff deadline.SO WHAT: If you purchased BlackRock TCP securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingenc ...

Core Viewpoint - A class action lawsuit has been filed against uniQure N.V. for misrepresentation and failure to disclose critical information regarding its drug candidate for Huntington's Disease, potentially affecting investors who purchased shares during the specified period [1][5]. Group 1: Lawsuit Announcement - Rosen Law Firm has announced a class action lawsuit on behalf of purchasers of uniQure ordinary shares between September 24, 2025, and October 31, 2025 [1]. - Investors who purchased shares during this period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. Group 2: Legal Process and Participation - Interested investors can join the class action by visiting the provided link or contacting the law firm directly [3][6]. - A lead plaintiff must be appointed by April 13, 2026, to represent the class in the litigation [1][3]. Group 3: Details of the Case - The lawsuit alleges that uniQure misrepresented the approval status of its Pivotal Study by the FDA and downplayed the likelihood of delays in its Biologics License Application (BLA) timeline [5]. - The claims suggest that the defendants' statements regarding uniQure's business and prospects lacked a reasonable basis, leading to investor damages when the truth was revealed [5]. Group 4: Law Firm Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements for investors, including over $438 million in 2019 [4]. - The firm has been recognized for its success in securities class action settlements and has a history of representing investors globally [4].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased agilon health, inc. securities during the specified Class Period of the upcoming lead plaintiff deadline for a securities class action lawsuit [1] Group 1: Class Action Details - The Class Period for the agilon securities is from February 26, 2025, to August 4, 2025 [1] - Investors who purchased agilon securities during this period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2] - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by March 2, 2026 [3] Group 2: Case Allegations - The lawsuit alleges that defendants made false or misleading statements and failed to disclose critical information, including unrealistic guidance for 2025 and overstated financial impacts from strategic actions [5] - The claims suggest that the defendants were aware of material industry headwinds that would prevent achieving the stated guidance [5] - As a result of these misleading statements, investors suffered damages when the true information became public [5] Group 3: Rosen Law Firm's Credentials - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions [4] - The firm has achieved significant settlements, including the largest securities class action settlement against a Chinese company, and has consistently ranked highly in securities class action settlements [4] - In 2019, the firm secured over $438 million for investors, showcasing its capability in recovering funds for clients [4]